Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles

Area of Science:

• Pharmacology
• Nanotechnology
• Drug Delivery

Background:

• Breviscapine (BVP) is a drug with potential therapeutic applications.
• Developing effective delivery systems for BVP is crucial for enhancing its efficacy.
• Poly (D, L-lactic acid) nanoparticles (BVP-PLA-NPs) offer a promising platform for drug delivery.

Purpose of the Study:

• To investigate the pharmacokinetics and biodistribution of free breviscapine (BVP) and coated BVP-loaded poly (D, L-lactic acid) nanoparticles (BVP-PLA-NPs) in rats.
• To evaluate the impact of nanoparticle size on BVP's pharmacokinetic and biodistribution profiles.
• To assess the ability of BVP-PLA-NPs to penetrate the blood-brain barrier (BBB).

Main Methods:

• Coated BVP-PLA-NPs were prepared using the spontaneous emulsification solvent diffusion method.
• Nanoparticle characterization included size, distribution, and morphology analysis.
• High-performance liquid chromatography (HPLC) was used to quantify BVP in biological samples and in vitro release studies.
• Pharmacokinetic and biodistribution studies were conducted in rats following intravenous administration.

Main Results:

• Coated BVP-PLA-NPs exhibited mean sizes of 177 nm and 319 nm with high entrapment efficiency.
• Drug release profiles showed biphasic release in phosphate buffer and plasma.
• Compared to free BVP, nanoparticle administration significantly increased the area under the plasma concentration-time curve and prolonged elimination half-life.
• NPs were primarily distributed in the liver, spleen, heart, and brain, demonstrating BBB penetration.

Conclusions:

• Coated BVP-PLA-NPs effectively avoid reticuloendothelial system capture, prolonging BVP's half-life.
• The nanoparticle formulation enhances BVP accumulation in the brain by penetrating the BBB.
• Particle size influences the pharmacokinetic and biodistribution of BVP-loaded nanoparticles.